Opthea

Opthea is the next name on the list of the largest biotech companies in Australia, it is a clinical-stage biopharmaceutical firm dedicated to finding innovative therapies to help people with retinal diseases enhance their visual function. Millions of people worldwide have poor vision as a result of diabetes and old age. The company's objective is to enhance eyesight so that people may live better lives.

In the first part of 2021, Opthea began two key Phase 3 clinical studies for the treatment of wet AMD. Opthea has completed three worldwide clinical studies in which OPT-302 was tested in two disease indications. Two of the studies were in wet AMD patients, including the first in a human Phase 1b/2a study, followed by a major randomized controlled Phase 2b study, and the third was in DME patients.

OPT-302, its first-in-class novel therapy, is a VEGF-C/D 'trap' that be utilized in combination with existing standard-of-care anti-VEGF-A medications to enhance vision in patients. It has the potential to address an unmet medical need in individuals with wet age-related macular degeneration (AMD) and diabetic macular edema (DME), many of whom respond suboptimally or develop resistance to conventional treatments for these debilitating diseases.

Founded: 2012

Headquarters: South Yarra, VIC, Australia

Website: https://opthea.com/